McMaster University Medical Centre
Hamilton, Ontario, L8N 3Z5, Canada
NCT Number: NCT05643131
This study seeks to address accessible management of endometriosis-associated chronic pelvic pain by evaluating a novel device used in the home. The study is designed as a proof-of-concept single-arm pilot study, and the primary objective is to assess change in overall self-reported pelvic pain in people with endometriosis-associated chronic pelvic pain following the use of the Hyivy intravaginal device.
Trial opening soon.
Get Notified18 year and older
Female
Interventional
Not applicable
Hamilton, Ontario, L8N 3Z5, Canada
Endometriosis is a chronic, inflammatory, estrogen-dependent disease characterized by ectopic growth of uterine-like cells outside the uterus. People living with endometriosis typically experience debilitating pelvic pain (dysmenorrhea, dyspareunia, dyschezia, dysuria, non-menstrual pelvic pain), and infertility. Endometriosis also has significant negative impacts on quality of life, physical, mental, and social wellbeing.
There is no diagnostic marker nor cure for this chronic disease. Current treatment options include medical therapies (mainly hormonal treatments aimed at suppressing menstruation or growth of the ectopic cells), surgery (to remove endometriotic lesions/nodules), and complementary or alternative therapies (non-medical or surgical options to manage symptoms; heat, mindfulness, diet, yoga, natural remedies, physical therapies, etc.).
Many people living with endometriosis report having used self-management strategies (complementary and alternative therapies) to manage their symptoms, and research on treatments and alternative therapies are consistently ranked among the top endometriosis research priorities. Alternative therapies have the potential to complement existing medical and surgical therapies, offering additional options to manage symptoms like pain.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Intravaginal use of Hyivy device three times per week for 12 weeks, with each session consisting of 10 minutes of heat (37-39ºC) and 10 minutes of dilation.
Time frame: Baseline, 6-weeks, 12-weeks
Overall pelvic pain will be evaluated using a digital visual analog scale (VAS)
Time frame: Baseline, 6-weeks, 12-weeks
Site-specific tenderness and pelvic floor muscle pain will be measured by the Biberoglu and Behrman scale (B&B) ranging from 0 (none) to 15 (severe) and patient exams
Time frame: Baseline, 6-weeks, 12-weeks
Changes in quality of life as assessed by the Endometriosis Health Profile-30 (EHP-30) ranging from 0 (best possible health status) to 100 (worst possible health status).
Time frame: Baseline, 6-weeks, 12-weeks
Changes in sexual function as assessed by the Female Sexual Function Index (FSFI). Scores range from 2 to 36 with higher scores indicating greater functioning.
Time frame: Up to 12-weeks
Occurrence of adverse events (AE) and serious adverse events (SAE).
Time frame: 6-weeks, 12-weeks
Usage data collected by the Hyivy device will be used to assess participant adherence to the study regimen of 3 times/week device use.
Time frame: 6-weeks, 12-weeks
Device usage will be assessed with a study-specific questionnaire.
Time frame: Baseline, 6-weeks, 12-weeks
Changes in the use of rescue medications for chronic pelvic pain, assessed with a study-specific questionnaire.
Time frame: Baseline, 6-weeks, 12-weeks
Autonomic nervous system (ANS) function will be assessed using measures of heart rate variability (HRV) during a deep breathing test, active standing test, and water intake test.
Time frame: Baseline, 6-weeks, 12-weeks
Changes in peripheral inflammation as assessed by a protein biomarker panel before and after device use
Time frame: Baseline, 6-weeks, 12-weeks
Number of ER visits due to chronic pelvic pain in the last 6 weeks
Time frame: 12-weeks
Study-specific questionnaire to gather patient feedback
Contact information is provided by the study sponsor or research team.
Hyivy Health Inc
Industry
Evaluation of the Hyivy Device as a Non-hormonal Therapy in People With Endometriosis
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07241637
Endometriosis, Fatigue
Ankara, Turkey (Türkiye)
View Trial DetailsNCT07305025
Endometriosis, Female Urogenital Diseases
Trondheim, Norway
View Trial DetailsNCT06611501
Chronic Pain, Endometriosis
Boston, Massachusetts, United States
View Trial DetailsNCT06101303
Endometriosis, Female Urogenital Diseases
St Louis, Missouri, United States
View Trial Details